1. Home
  2. STKS vs XLO Comparison

STKS vs XLO Comparison

Compare STKS & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The ONE Group Hospitality Inc.

STKS

The ONE Group Hospitality Inc.

HOLD

Current Price

$1.59

Market Cap

52.7M

ML Signal

HOLD

XLO

Xilio Therapeutics Inc.

N/A

Current Price

$8.93

Market Cap

56.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
STKS
XLO
Founded
2004
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
52.7M
56.9M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
STKS
XLO
Price
$1.59
$8.93
Analyst Decision
Strong Buy
Buy
Analyst Count
3
1
Target Price
$4.70
$28.00
AVG Volume (30 Days)
16.1K
9.5K
Earning Date
05-04-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$805,722,000.00
$43,766,000.00
Revenue This Year
$7.47
N/A
Revenue Next Year
$8.12
$168.77
P/E Ratio
N/A
N/A
Revenue Growth
19.66
589.88
52 Week Low
$1.62
$0.46
52 Week High
$3.38
$9.90

Technical Indicators

Market Signals
Indicator
STKS
XLO
Relative Strength Index (RSI) 36.52 48.51
Support Level N/A $8.52
Resistance Level $2.00 $9.15
Average True Range (ATR) 0.04 0.29
MACD 0.00 -0.02
Stochastic Oscillator 38.89 57.33

Price Performance

Historical Comparison
STKS
XLO

About STKS The ONE Group Hospitality Inc.

The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through three segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Share on Social Networks: